Dr. Jonathan Lim Yamzon, MD

Dr. Yamzon practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Yamzon's NPI, 1093943854, was assigned on June 30, 2009. Dr. Yamzon graduated from Keck School of Medicine of USC in 2004. Dr. Yamzon holds California license A95822.

Dr. Yamzon's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Yamzon's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Yamzon to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yamzon practices. Vendor and product names are available with a free account.

Urology is Dr. Yamzon's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Yamzon is board certified in clinical informatics by the American Board of Emergency Medicine. Dr. Yamzon is licensed in California.

Dmand AI lists bladder removal, enlarged prostate, kidney removal surgery, kidney stone disease, prostate cancer, prostate surgery and urinary endoscopy among the conditions Dr. Yamzon treats.

CMS data shows 360 Medicare services from Dr. Yamzon across 10 procedure codes in 2024, for 165 Medicare patients. Medicare paid $47,503 for them.

CMS counts 165 Medicare patients who saw Dr. Yamzon in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yamzon's median patient age at 72, with 21% women.

In 2024, Dr. Yamzon wrote 57 Medicare Part D claims for 33 patients. 98% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $27 in total drug cost. In 2023, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Yamzon for performance year 2024, reported as part of a group. Dr. Yamzon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Yamzon as offering telehealth.

Hernia repair - groin (open): 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 19 papers to Dr. Yamzon, published from 2012 to 2024. 2017 was the busiest year, with 3. The most frequent topics are Cystectomy, Robotic Surgical Procedures and Urinary Bladder Neoplasms. Dr. Yamzon has published most often in Clin Genitourin Cancer. Dr. Yamzon's most frequent co-authors are Clayton S. Lau, MD, Bertram Emmanuel Yuh, MD and Kevin G. Chan, MD.

Dmand AI links Dr. Yamzon to 1 clinical trial. Conditions studied include Postoperative Complications and Prostatic Neoplasms.

CMS Open Payments shows 33 general payments to Dr. Yamzon from 16 drug and device companies from 2016 to 2025. Education make up the largest share, 60% of the total. Intuitive Surgical, Inc. paid the most, $3,306.

Dr. Yamzon graduated from Keck School of Medicine of USC in 2004.

Dr. Yamzon is in network with 13 carriers, including Elevance, Aetna and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.